FINWIRES · TerminalLIVE
FINWIRES

Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38

By

Capricor Therapeutics (CAPR) has an average rating of Buy and mean price target of $45.20, according to analysts polled by FactSet.

What else is happening in Research?